Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)

v3.19.3
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock [Member]
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Treasury Stock
Total
Beginning balance, shares at Dec. 31, 2017 3,090,742 753,659          
Beginning balance, value at Dec. 31, 2017 $ 3,090 $ 754 $ 165,258,198 $ (145,933,137) $ 253,734 $ (5,281,180) $ 14,301,459
Exercise of warrants, shares 30,834          
Exercise of warrants, value $ 31 1,479,969   1,480,000
Conversion of Series B preferred stock to shares of common stock, shares (316,348) 26,363          
Conversion of Series B preferred stock to shares of common stock, value $ (316) $ 26 290  
Share-based expense 1,123,000 1,123,000
Common stock awards to vendors 52,281 52,281
Net loss (5,661,230) (5,661,230)
Ending balance, shares at Sep. 30, 2018 2,774,394 810,856          
Ending balance, value at Sep. 30, 2018 $ 2,774 $ 811 167,913,738 (151,594,367) 253,734 (5,281,180) 11,295,510
Beginning balance, shares at Jun. 30, 2018 2,774,394 810,856          
Beginning balance, value at Jun. 30, 2018 $ 2,774 $ 811 167,590,260 (149,781,831) 253,734 (5,281,180) 12,784,568
Share-based expense 306,051 306,051
Common stock awards to vendors 17,427 17,427
Net loss (1,812,536) (1,812,536)
Ending balance, shares at Sep. 30, 2018 2,774,394 810,856          
Ending balance, value at Sep. 30, 2018 $ 2,774 $ 811 167,913,738 (151,594,367) 253,734 (5,281,180) 11,295,510
Beginning balance, shares at Dec. 31, 2018 2,774,394 810,856          
Beginning balance, value at Dec. 31, 2018 $ 2,774 $ 811 168,170,244 (153,233,595) 253,734 (5,281,180) 9,912,788
Issuance of common stock and warrants in registered direct offering, net of issuance costs, shares 86,667          
Issuance of common stock and warrants in registered direct offering, net of issuance costs, value $ 87 2,698,963 2,699,050
Issuance of common stock and warrants in public offering, net of issuance costs, shares 1,746,666          
Issuance of common stock and warrants in public offering, net of issuance costs, value $ 1,747 13,420,203 13,421,950
Issuance of common stock in connection with purchase of in-process research and development, shares 624,995          
Issuance of common stock in connection with purchase of in-process research and development, value $ 625 3,030,601 3,031,226
Exercise of pre-funded warrants, shares 492,417          
Exercise of pre-funded warrant, value $ 492 4,517 5,009
Exercise of purchase warrants, shares 1,889,602          
Exercise of purchase warrants, value $ 1,890 (1,890)
Issuance of common stock to vendor, shares 7,836          
Issuance of common stock to vendor, value $ 7 (7)
Issuance of warrants in connection with reverse stock split, shares          
Issuance of warrants in connection with reverse stock split, value 63,536 63,536
Issuance of common stock to adjust for reverse split rounding, shares 1,442          
Issuance of common stock to adjust for reverse split rounding, value $ 1 (1)
Deemed dividend related to Series B Preferred Stock down round provision 5,284,379 5,284,379
Accretion of deemed dividend related to Series B Preferred Stock down round provision (5,284,379) (5,284,379)
Share-based expense 683,104 683,104
Common stock awards to vendors 47,427 47,427
Net loss (11,604,778) (11,604,778)
Ending balance, shares at Sep. 30, 2019 2,774,394 5,660,481          
Ending balance, value at Sep. 30, 2019 $ 2,774 $ 5,660 188,116,697 (164,838,373) 253,734 (5,281,180) 18,259,312
Beginning balance, shares at Jun. 30, 2019 2,774,394 949,218          
Beginning balance, value at Jun. 30, 2019 $ 2,774 $ 948 171,352,760 (155,938,245) 253,734 (5,281,180) 10,390,791
Issuance of common stock and warrants in public offering, net of issuance costs, shares 1,746,666          
Issuance of common stock and warrants in public offering, net of issuance costs, value $ 1,747 13,420,203 13,421,950
Issuance of common stock in connection with purchase of in-process research and development, shares 624,995          
Issuance of common stock in connection with purchase of in-process research and development, value $ 625 3,030,601 3,031,226
Exercise of pre-funded warrants, shares 450,000          
Exercise of pre-funded warrant, value $ 450 4,050 4,500
Exercise of purchase warrants, shares 1,889,602          
Exercise of purchase warrants, value $ 1,890 (1,890)
Issuance of warrants in connection with reverse stock split, shares          
Issuance of warrants in connection with reverse stock split, value 63,536 63,536
Deemed dividend related to Series B Preferred Stock down round provision 1,404,932 1,404,932
Accretion of deemed dividend related to Series B Preferred Stock down round provision (1,404,932) (1,404,932)
Share-based expense 232,437 232,437
Common stock awards to vendors 15,000 15,000
Net loss (8,900,128) (8,900,128)
Ending balance, shares at Sep. 30, 2019 2,774,394 5,660,481          
Ending balance, value at Sep. 30, 2019 $ 2,774 $ 5,660 $ 188,116,697 $ (164,838,373) $ 253,734 $ (5,281,180) $ 18,259,312